Residual lung damage after completion of treatment for multidrug-resistant tuberculosis
- PMID: 15182148
Residual lung damage after completion of treatment for multidrug-resistant tuberculosis
Abstract
Setting: Limpopo Province, South Africa.
Objective: To assess the residual lung damage of patients who completed treatment for multidrug-resistant tuberculosis (MDR-TB).
Design: Chest radiograph and lung function tests were performed at the end of treatment. The radiographs were read by two independent observers who attributed a zonal score of between 0 and 18, depending on the extent of radiographic abnormalities (opacification or cavitation), counted the number of visible cavities and measured the diameter of the largest cavity.
Results: The mean zonal score was 6.5. Cavitation was present in more than half of the patients. Of 33 patients, 31 (94%) had abnormal lung function tests. The median FEV1 was 63% and FVC was 57% of the predicted value. Restrictive and combined restrictive-obstructive lung function patterns were the predominant abnormalities.
Conclusions: Residual lung damage in MDR-TB patients who completed treatment is common and extensive. This may increase the risk of relapse of tuberculosis and reduce the quality of life and life expectancy of these patients. Additional efforts are warranted to diagnose MDR-TB early to reduce the extent of residual lung damage. Close follow-up of MDR-TB patients completing treatment will have to be ensured to detect relapses.
Similar articles
-
Computed tomography features of extensively drug-resistant pulmonary tuberculosis in non-HIV-infected patients.J Comput Assist Tomogr. 2010 Jul;34(4):559-63. doi: 10.1097/RCT.0b013e3181d472bc. J Comput Assist Tomogr. 2010. PMID: 20657225
-
Relationship between self reporting of past history of anti-tuberculosis treatment and radiographic findings in multidrug-resistant tuberculosis.Int J Tuberc Lung Dis. 2004 Nov;8(11):1385-7. Int J Tuberc Lung Dis. 2004. PMID: 15581211
-
Radiographic findings and patterns in multidrug-resistant tuberculosis.J Thorac Imaging. 1998 Jan;13(1):65-71. doi: 10.1097/00005382-199801000-00015. J Thorac Imaging. 1998. PMID: 9440843
-
[Drug resistant tuberculosis].Pol Merkur Lekarski. 2011 May;30(179):362-6. Pol Merkur Lekarski. 2011. PMID: 21675144 Review. Polish.
-
Multidrug resistant tuberculosis: trends and control.Indian J Chest Dis Allied Sci. 2014 Oct-Dec;56(4):237-46. Indian J Chest Dis Allied Sci. 2014. PMID: 25962197 Review.
Cited by
-
The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function.Eur Respir J. 2020 Mar 12;55(3):1901692. doi: 10.1183/13993003.01692-2019. Print 2020 Mar. Eur Respir J. 2020. PMID: 31862762 Free PMC article.
-
Determinants of Restrictive Spirometric Pattern in a Sub-Saharan Urban Setting: A Cross-sectional Population-based Study.Open Respir Med J. 2016 Nov 30;10:86-95. doi: 10.2174/1874306401610010086. eCollection 2016. Open Respir Med J. 2016. PMID: 28144367 Free PMC article.
-
Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?J Bras Pneumol. 2016 Sep-Oct;42(5):374-385. doi: 10.1590/S1806-37562016000000226. J Bras Pneumol. 2016. PMID: 27812638 Free PMC article.
-
Sequelae of pulmonary multidrug-resistant tuberculosis at the completion of treatment.Lung India. 2018 Jan-Feb;35(1):4-8. doi: 10.4103/lungindia.lungindia_269_16. Lung India. 2018. PMID: 29319026 Free PMC article.
-
The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy.Front Microbiol. 2018 Oct 30;9:2603. doi: 10.3389/fmicb.2018.02603. eCollection 2018. Front Microbiol. 2018. PMID: 30425706 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources